Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structure and function of placental growth factor.

Sandro De Falco1, Bruna Gigante, M Graziella Persico

  • 1International Institute of Genetics and Biophysics, CNR, Napoli, Italy

Trends in Cardiovascular Medicine
|September 21, 2002
PubMed
Summary

Placental growth factor (PlGF) plays a key role in pathological angiogenesis, despite normal development. Targeting the PlGF/VEGFR-1 pathway may offer a novel therapeutic approach for stimulating blood vessel growth.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risks. A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular Pharmacology A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular Pharmacology.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same author

Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risks.

European heart journal. Acute cardiovascular care·2026
Same author

The therapeutic effects of the VEGF decoy receptor fusion protein VEGF-Grab in chronic inflammatory diseases.

EBioMedicine·2026
Same author

Prolyl 3-Hydroxylase 2 Supports a Pro-Angiogenic Milieu Promoting Colorectal Cancer Progression and Metastasis.

International journal of molecular sciences·2026
Same author

Hospitalizations for cardiovascular events and risk for all cause and cardiovascular mortality in elderly patients with atrial fibrillation treated with oral anticoagulants: beyond preventing thromboembolism.

BMC geriatrics·2025
Same author

A multi-omics approach uncovers causality of IL6R on endotypes of subclinical carotid atherosclerosis and the possible role of the IL6R/OSMR pathway.

Cardiovascular research·2025

Area of Science:

  • Vascular biology
  • Molecular medicine
  • Angiogenesis research

Background:

  • Placental growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family.
  • VEGF-A is crucial for therapeutic angiogenesis, but clinical results are controversial.
  • PlGF and its receptor VEGFR-1 are implicated in pathological angiogenesis.

Purpose of the Study:

  • To investigate the role of PlGF and VEGFR-1 in angiogenesis.
  • To explore the PlGF/VEGFR-1 pathway as a potential therapeutic target for angiogenic therapy.

Main Methods:

  • Gene inactivation studies in mice to assess PlGF function.
  • Analysis of mice expressing a truncated VEGF receptor 1 (VEGFR-1).
  • Review of existing literature on VEGF-A therapeutic applications.

Related Experiment Videos

Main Results:

  • Loss of PlGF in mice did not affect normal development or reproduction.
  • PlGF-deficient mice exhibited impaired angiogenesis and arteriogenesis in pathological conditions.
  • Mice with truncated VEGFR-1 showed similar defects in angiogenesis.

Conclusions:

  • The PlGF/VEGFR-1 pathway is critical for regulating VEGF-A-dependent angiogenesis under pathological conditions.
  • The PlGF/VEGFR-1 pathway represents a promising alternative target for angiogenic therapies.
  • Further research into PlGF/VEGFR-1 signaling could advance treatments for ischemic diseases.